NICE Recommends Novartis’ Beovu for Diabetic Macular Edema

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Beovu (brolucizumab) for National Health Service (NHS) use for treatment of patients with diabetic macular edema, an eye condition associated with diabetes that can cause vision problems or blindness.

The recommended dose is 6 mg brolucizumab (0.05 ml solution) administered by injection every 6 weeks for the first 5 doses.

Depending on whether there is ongoing disease activity, patients may then receive treatments either every eight weeks or every twelve weeks.

The drug’s UK list price is approximately $990 per 1 ml vial. The negotiated price for NHS use was not disclosed.